[Compound Amino Acid Capsules combined with clomiphene for severe oligospermia]

To study the effect of Compound Amino Acid Capsules (CAAC) combined with clomiphene in the treatment of severe oligospermia.

A total of 104 patients with severe oligospermia admitted to our Center of Reproductive Medicine from January to September 2018 were randomly assigned to a trial (n = 60) and a control group (n = 44), the former treated by oral administration of CAAC combined with clomiphene and the latter with clomiphene only, both for 12 weeks. Comparisons were made between the two groups of patients in the sperm concentration, and the percentages of progressively motile sperm (PMS) and total motile sperm (TMS) before and after 4, 8 and 12 weeks of medication as well as the pregnancy rate during the treatment.

Compared with the baseline, the trial group showed significant elevation at 4, 8 and 12 weeks in sperm concentration (［3.13 ± 1.29］ vs ［12.06 ± 2.24］, ［22.10 ± 2.65］ and ［28.13 ± 3.59］ ×10⁶/ml, P < 0.01), PMS (［14.03 ± 2.49］% vs ［21.05 ± 3.14］%, ［29.08 ± 4.70］% and ［35.08 ± 3.70］%, P < 0.01) and TMS (［20.10 ± 4.05］% vs ［27.10 + 4.87］%, ［36.09 ± 5.64］% and ［45.04 ± 6.69］%, P < 0.01), and so did the control group in sperm concentration (［3.27 ± 1.46］ vs ［10.21 ± 2.35］, ［19.89 ± 2.74］ and ［25.23 ± 3.69］ ×10⁶/ml, P < 0.01), PMS (［13.32 ± 3.12］% vs ［17.02 ± 3.26］%, ［22.13 ± 3.70］% and ［27.18 ± 2.54］%, P < 0.01) and TMS (［21.30 ± 4.87］% vs ［24.22 ± 5.07］%, ［30.03 ± 5.33］% and ［35.05 ± 5.69］%, P < 0.01), even more significant in the trial than in the control group at the three time points after medication (P < 0.01). The pregnancy rate was markedly higher in the former than in the latter group at 4 (1.72% vs 0.53%, P < 0.01), 8 (4.21% vs 2.87%, P < 0.01) and 12 weeks (8.32% vs 6.32%, P < 0.01). No adverse reactions were observed in neither of the two groups during the treatment.

CAAC combined with clomiphene can significantly improve the semen parameters of the patients with severe oligospermia, with no obvious adverse events.